How I treat early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) in children.


Journal

Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509

Informations de publication

Date de publication:
16 Feb 2024
Historique:
accepted: 01 02 2024
received: 18 12 2023
revised: 19 01 2024
medline: 16 2 2024
pubmed: 16 2 2024
entrez: 16 2 2024
Statut: aheadofprint

Résumé

Early T-precursor acute lymphoblastic leukemia (ETP-ALL) is a unique subtype of immature T-ALL that was initially associated with a dramatically inferior prognosis as compared to non-ETP T-ALL (Not-ETP) when it was first described in 2009. Analyses of larger patient cohorts treated with more contemporary regimens, however, have shown minimal survival differences between ETP and Not-ETP. In this manuscript we utilize representative cases to explore therapeutic advances and address common clinical questions regarding management of children, adolescents, and young adults with ETP-ALL. We describe our recommended treatment approach for a child or adolescent with newly diagnosed ETP-ALL, with an emphasis on the prognostic significance of induction failure and detectable minimal residual disease and the role for hematopoietic stem cell transplant in first remission. We discuss the interplay between the ETP immunophenotype and genomic markers of immaturity in T-ALL. Finally, we review novel therapeutic approaches that should be considered when managing relapsed or refractory ETP-ALL.

Identifiants

pubmed: 38364183
pii: 514992
doi: 10.1182/blood.2023023155
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 American Society of Hematology.

Auteurs

Ryan J Summers (RJ)

Emory University, United States.

David Trent Teachey (DT)

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States.

Stephen P Hunger (SP)

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States.

Classifications MeSH